<DOC>
	<DOCNO>NCT01558271</DOCNO>
	<brief_summary>The purpose trial examine efficacy safety once-weekly LY2189265 participant type 2 diabetes mellitus take oral antidiabetic medication .</brief_summary>
	<brief_title>A Study LY2189265 Japanese Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Rescue therapy ( defined alternative antihyperglycemic medication use dose modification oral antihyperglycemic medication [ OAM ] ) may initiate planned treatment period participant discontinue study drug meet prespecified threshold severe , persistent hyperglycemia . Efficacy data , well data hypoglycemic episode participant permanently discontinue study treatment switch another diabetes medication remain study , censor point initiate new treatment onwards .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Participants diagnosis type 2 diabetes mellitus screen . Participants Oral Antihyperglycemic Medication ( OAM ) naïve ( diet exercise ) take OAM monotherapy except thiazolidinedione ( TZD ) willing discontinue medication . Participants take OAM monotherapy must complete 8week washout period prior randomization . Participants OAM naïve screen glycosylated hemoglobin ( HbA1c ) value 7.0 % 10.0 % randomization HbA1c value 7.0 % 10.0 % , take OAM monotherapy screen HbA1c value 6.5 % 9.0 % randomization HbA1c value 7.0 % 10.0 % . Participants body mass index ( BMI ) 18.5 kilogram per meter square ( kg/m^2 ) 35.0 kg/m^2 . Participants diagnosis type 1 diabetes . Participants previously treat glucagonlike peptide1 ( GLP1 ) analog . Participants receive half maximum dose sulfonylurea screen . Participants currently take insulin TZD , previous insulin TZD treatment within 3 month screen . Participants obvious clinical sign symptom pancreatitis , history chronic pancreatitis acute pancreatitis screening , determine investigator . Participants serum amylase concentration ≥3 time upper limit reference range and/or serum lipase concentration ≥2 time upper limit reference range , determined central laboratory screening . Participants self family history medullary Ccell hyperplasia , focal hyperplasia , medullary thyroid carcinoma ( MTC ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>GLP-1</keyword>
</DOC>